Amarin’s Value Could Plunge If Heart Drug Patent Suit Is Lost
This article is for subscribers only.
Analysts have cautioned Amarin Corp.’s share price could be cut in half after a key patent decision for its cardiovascular medicine Vascepa, expected in March.
A federal judge in Las Vegas is considering the company’s patent-infringement complaint that seeks to block generic versions of the drug until six patents expire in 2030. A non-jury trial was heard in January before District Court Judge Miranda Du, and both sides are submitting their post-trial arguments to the court by Friday.